Understanding key regulators of normal skeletal function have been facilitated by the study of osteogenesis imperfecta (01) or brittle bone disease. Our genetic studies have shown that humans with loss of function mutations in FKBPIO (which encodes the FKBP65 protein) have progressive deforming 01, which may also be associated with progressive joint contractures. What remains unresolved, but necessary to understand, are the cellular consequences and molecular interactions by which FKBP65 regulates synthesis of type I procollagen and formation of a proper bone extracellular matrix (ECM) leading to normal mineralization.
The Specific Aims are: 1. Determine the consequences of FKBP10 loss on cellular phenotype. Loss of FKBP65 has significant effects on cellular phenotype indicating increased ER stress. We will determine the molecular basis for these observations in human 01 cells. 2. Determine the in vivo role of FKBP65 in mesenchymally derived tissues and determine its interaction with other ER-localized proteins. FkbpIO conditional knockout mice have been generated to determine whether the abnormal human cellular phenotype is recapitulated in the mouse. Based on the human phenotype, we will determine tissue-specific roles for Fkbp65 in the FkbpIO null mice.. 3. Determine the molecular basis for other recessive forms of 01. Using autozygosity mapping we have identified three new loci for recessively inherited forms of 01. We hypothesize that, like most genes associated with 01, these genes will be involved in the processing of type I procollagen and that their identification will reveal additional components essential for bone formation. We will use exome sequencing of genes in the autozygous regions to define these new 01 associated genes. The work proposed will determine the role of FKBP10/FKBP65 in mesenchymal tissues and will define new components necessary for normal bone formation. Overall the data generated will determine the molecules necessary for the synthesis, mineralization and maintenance of a normal type I collagen extracellular matrix.
The results of this project will have an immediate impact by providing improved genetic counseling and diagnostic testing for families with brittle bone disease. Determining the mechanism of disease in these new forms of Ol develop will identify disease-based strategies and specific molecular targets for therapy.
|Lietman, Caressa D; Marom, Ronit; Munivez, Elda et al. (2015) A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res 30:489-98|
|Homan, Erica P; Lietman, Caressa; Grafe, Ingo et al. (2014) Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues. PLoS Genet 10:e1004121|
|Hudson, David M; Werther, Rachel; Weis, MaryAnn et al. (2014) Evolutionary origins of C-terminal (GPP)n 3-hydroxyproline formation in vertebrate tendon collagen. PLoS One 9:e93467|
|Joeng, Kyu Sang; Lee, Yi-Chien; Jiang, Ming-Ming et al. (2014) The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. Hum Mol Genet 23:4035-42|
|Murali, Chaya; Lu, James T; Jain, Mahim et al. (2014) Diagnosis of ALG12-CDG by exome sequencing in a case of severe skeletal dysplasia. Mol Genet Metab Rep 1:213-219|
|Martin, Brett M; Ivanova, Margarita H; Sarukhanov, Anna et al. (2014) Prenatal and postnatal findings in serpentine fibula polycystic kidney syndrome and a review of the NOTCH2 spectrum disorders. Am J Med Genet A 164A:2490-5|
|Rajagopal, Abbhirami; Braslavsky, Débora; Lu, James T et al. (2014) Exome sequencing identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis. J Clin Endocrinol Metab 99:E2451-6|
|Chen, Shan; Lee, Brendan H; Bae, Yangjin (2014) Notch signaling in skeletal stem cells. Calcif Tissue Int 94:68-77|
|Tao, Jianning; Jiang, Ming-Ming; Jiang, Lichun et al. (2014) Notch activation as a driver of osteogenic sarcoma. Cancer Cell 26:390-401|
|Posey, Jennifer E; Burrage, Lindsay C; Miller, Marcus J et al. (2014) Lysinuric Protein Intolerance Presenting with Multiple Fractures. Mol Genet Metab Rep 1:176-183|
Showing the most recent 10 out of 24 publications